Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Native Antigen Company is a leading global supplier of high-quality infectious disease reagents—antigens and antibodies—used in diagnostics and vaccine research. It does not develop therapeutics but provides critical components for R&D in emerging infectious diseases. Its proprietary VirtuE™ system enables production of native-like proteins with correct folding/glycosylation. In 2020 it was acquired by LGC Group to expand its manufacturing capacity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on The Native Antigen Company.